| Psoriasis vulgaris
Enstilar vs Siliq
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Enstilar vs Siliq with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSiliq has a higher rate of injection site reactions vs Enstilar based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Siliq but not Enstilar, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Enstilar
Siliq
At A Glance
Topical
Once daily
Vitamin D3 analog + corticosteroid
Subcutaneous
Every 2 weeks
IL-17RA antagonist
Indications
- Psoriasis vulgaris
- Psoriasis vulgaris
Dosing
Psoriasis vulgaris Apply to affected areas once daily for up to 4 weeks; maximum dose not to exceed 60 g every 4 days; rub in gently; do not use with occlusive dressings, on the face, groin, or axillae, or if skin atrophy is present at the treatment site.
Psoriasis vulgaris 210 mg subcutaneously at Weeks 0, 1, and 2 followed by 210 mg every 2 weeks.
Contraindications
—
- Crohn's disease
- Clinically significant hypersensitivity to brodalumab or to any of the excipients
Adverse Reactions
Postmarketing Application site burning, atrophy, striae, telangiectasia, dryness, perioral dermatitis, secondary infection, miliaria, cataracts, glaucoma, increased intraocular pressure.
Most common (>=1%) Arthralgia (4.7%), headache (4.3%), fatigue (2.6%), diarrhea (2.2%), oropharyngeal pain (2.1%), nausea (1.9%), myalgia (1.7%), injection site reactions (1.5%), influenza (1.3%), neutropenia (1.0%), tinea infections (1.0%).
Serious Suicidal ideation and behavior (0.37 per 100 subject-years), infections including fungal infections, neutropenia grade >=3.
Postmarketing Hypersensitivity reactions, anaphylaxis including anaphylactic shock, pruritus, rashes, eczema, urticaria, dermatitis, eczematous eruptions (atopic dermatitis-like eruptions).
Pharmacology
Enstilar Foam combines calcipotriene hydrate, a synthetic vitamin D3 analog, and betamethasone dipropionate, a synthetic corticosteroid; exact mechanisms of action in the treatment of plaque psoriasis are unknown.
Brodalumab is a human monoclonal IgG2 antibody that selectively binds to IL-17RA and inhibits its interactions with IL-17 family cytokines (IL-17A, IL-17F, IL-17C, IL-17A/F heterodimer, IL-25), thereby blocking IL-17 cytokine-induced pro-inflammatory responses.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Enstilar
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (10/12) · Qty limit (9/12)
Siliq
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Enstilar
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (3/8)
Siliq
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Enstilar
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Siliq
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$30/fillfill
Leo Copay Savings Card: EnstilarCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
$50/momo
Siliq Solutions Instant Savings Program - Non-covered benefitCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EnstilarView full Enstilar profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.